- Home
- SBRA vs BCTXZ Comparison
SBRA vs BCTXZ Comparison
Compare SBRA & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- BCTXZ
- Stock Information
- Founded
- SBRA 2010
- BCTXZ N/A
- Country
- SBRA United States
- BCTXZ Canada
- Employees
- SBRA N/A
- BCTXZ 12
- Industry
- SBRA Real Estate Investment Trusts
- BCTXZ
- Sector
- SBRA Real Estate
- BCTXZ
- Exchange
- SBRA Nasdaq
- BCTXZ Nasdaq
- Market Cap
- SBRA N/A
- BCTXZ N/A
- IPO Year
- SBRA N/A
- BCTXZ N/A
- Fundamental
- Price
- SBRA $18.31
- BCTXZ $1.06
- Analyst Decision
- SBRA Buy
- BCTXZ
- Analyst Count
- SBRA 7
- BCTXZ 0
- Target Price
- SBRA $19.71
- BCTXZ N/A
- AVG Volume (30 Days)
- SBRA 2.7M
- BCTXZ N/A
- Earning Date
- SBRA 08-06-2025
- BCTXZ N/A
- Dividend Yield
- SBRA 6.55%
- BCTXZ N/A
- EPS Growth
- SBRA 185.79
- BCTXZ N/A
- EPS
- SBRA 0.60
- BCTXZ N/A
- Revenue
- SBRA $720,247,000.00
- BCTXZ N/A
- Revenue This Year
- SBRA $5.91
- BCTXZ N/A
- Revenue Next Year
- SBRA $5.30
- BCTXZ N/A
- P/E Ratio
- SBRA $30.58
- BCTXZ N/A
- Revenue Growth
- SBRA 10.76
- BCTXZ N/A
- 52 Week Low
- SBRA $15.11
- BCTXZ N/A
- 52 Week High
- SBRA $20.03
- BCTXZ N/A
- Technical
- Relative Strength Index (RSI)
- SBRA 57.85
- BCTXZ N/A
- Support Level
- SBRA $18.10
- BCTXZ N/A
- Resistance Level
- SBRA $18.70
- BCTXZ N/A
- Average True Range (ATR)
- SBRA 0.38
- BCTXZ 0.00
- MACD
- SBRA 0.01
- BCTXZ 0.00
- Stochastic Oscillator
- SBRA 71.43
- BCTXZ 0.00
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.